Extended duration of letermovir prophylaxis: how long is long enough?
- PMID: 38142694
- DOI: 10.1016/S2352-3026(23)00368-X
Extended duration of letermovir prophylaxis: how long is long enough?
Conflict of interest statement
APD has received honoraria paid to her institution from Gilead Sciences. MAS has received grants to her institution from F2G and Merck, honoraria paid to her institution by Shionogi, and participated on the data safety monitoring board of trials by Roche and Pfizer.
Comment on
-
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Haematol. 2024 Feb;11(2):e127-e135. doi: 10.1016/S2352-3026(23)00344-7. Epub 2023 Dec 21. Lancet Haematol. 2024. PMID: 38142695 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources